Target intelligence / Profile preview

Helicase POLQ-like (HELQ)

Target
HELQ
Molecular classification
Enzyme (specifically DNA helicase), Superfamily II helicase, ssDNA-dependent ATPase
01

Overview

Helicase POLQ-like (HELQ) is an ATP-dependent DNA helicase that plays a key role in DNA repair, especially at stalled replication forks, by unwinding DNA and facilitating homologous recombination and other repair mechanisms[1][2][4][5]. HELQ interacts with DNA repair proteins such as replication protein A (RPA) and RAD51 and is essential for maintaining genome stability, resolving DNA damage, and promoting cell survival following genotoxic stress[1][4][5]. It belongs to the Superfamily II group of helicases and acts with a 3’-5’ polarity[1][2][4]. HELQ deficiency increases sensitivity to DNA crosslinking agents and predisposes individuals to ovarian and pituitary tumors, as well as infertility due to germ cell loss[2][4]. Although not currently directly targeted by drugs, HELQ’s role in repair of therapy-induced DNA damage makes it a potential future cancer therapeutic target, and its mutations have diagnostic and prognostic relevance in ovarian cancer[2][3][4][5].

Other names
HELQHEL308Hel308Holliday junction migration proteinMus308-like helicaseDNA helicase HEL308POLQ-like helicasemus308-like helicase
02

Mechanism of action

Not applicable directly; however, chemotherapy agents that cause DNA crosslinks or replication-blocking lesions (e.g., cisplatin, mitomycin C) exert increased cytotoxicity when HELQ function is absent or impaired, because DNA repair processes are compromised[4][5].

03

Biological functions

DNA repair (especially at stalled replication forks)DNA unwindingDNA strand annealingGenome stability maintenanceHomologous recombinationNucleotide excision repairResolution of DNA interstrand crosslinksDouble-strand break repairMicro-homology mediated end joiningSingle-strand annealing
04

Disease associations

Cancer (predominantly ovarian and pituitary tumors, increased risk when HELQ is deficient)Infertility (germ cell loss in knockout animals)Genome instability
05

Safety considerations

Therapeutic inhibition could compromise genome stability, increasing risk of secondary malignancies or genetic defectsLoss-of-function mutations may predispose to infertility (especially germ cell loss) and tumor formation
06

Interacting drugs

cisplatin

1 more in the full profile.

07

Biomarkers

No clinically validated biomarkers for HELQ specifically used in patient selection or efficacy monitoringPotential: HELQ deficiency or mutations may serve as a biomarker for ovarian cancer predisposition and response to DNA damaging therapy

Beyond the preview

Go deeper on Helicase POLQ-like (HELQ).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Helicase POLQ-like (HELQ).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call